Pharmaceuticals News and Research

RSS

Study offers new way to suppress growth factors related to cancer cell proliferation

Cancer cells need life-essential molecules to proliferate. These so-called growth factors are activated by ectodomain shedding of precursor proteins on the outside of the plasma membrane, mainly carried out by three human cleavage enzymes. A pharmaceutical blocking of these enzymes could hinder cancer from growing but would also inhibit other life-essential processes.

13 Jul 2015

Envarsus XR receives FDA approval for treatment of kidney transplant recipients

Veloxis Pharmaceuticals A/S today announced U.S. Food and Drug Administration approval of Envarsus XR (tacrolimus extended-release tablets) for the prophylaxis of rejection in kidney transplant patients who require or desire conversion from other twice-daily tacrolimus products to once-daily Envarsus XR.

11 Jul 2015

Four young scientists named recipients of Damon Runyon-Sohn Pediatric Cancer Research Fellowship Award

The Damon Runyon Cancer Research Foundation has named four outstanding young scientists as recipients of the prestigious Damon Runyon-Sohn Pediatric Cancer Research Fellowship Award, committing nearly $875,000 to help address a critical shortage of funding for pediatric cancer research.

10 Jul 2015

Tillotts Pharma to purchase global rights for AstraZeneca’s Entocort excluding the U.S.

Tillotts Pharma AG, part of the Zeria Group, announced today that it has entered into an agreement for the acquisition of the global rights for Entocort (budesonide) from AstraZeneca, excluding the U.S., which will remain with AstraZeneca.

9 Jul 2015

Elsevier, NCI implement two-way linking between research articles on ScienceDirect and datasets in caNanoLab

Elsevier, a world-leading provider of scientific, technical and medical information products and services, and the US National Cancer Institute, a world-leading institute for cancer research, today announced that they have implemented two-way linking between research articles on ScienceDirect and datasets stored in NCI's cancer Nanotechnology Laboratory (caNanoLab) data portal.

9 Jul 2015

Sorrento, NantBioScience form joint venture to develop targeted therapies against cancer

Sorrento Therapeutics, Inc. and NantBioScience, Inc., a majority owned subsidiary of NantWorks, LLC, announced today that they have established a joint venture to focus on the development of 'first-in-class' small molecules against targets that have eluded the pharmaceutical industry to date and which may address important drivers of cancer growth including cancer stem cells.

9 Jul 2015

Phase 3 ODYSSEY JAPAN trial of Praluent injection meets primary endpoint

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the Phase 3 ODYSSEY JAPAN trial of the investigational therapy Praluent® (alirocumab) Injection met its primary endpoint.

9 Jul 2015

Partnerships between healthcare insurers and pharmaceutical companies promote real-world value

PwC's Health Research Institute (HRI) reports that market forces are driving new sector collaborations– pairing traditional drug makers with insurers, health systems, patient groups and technology firms – to maximize real-world value and health outcomes.

9 Jul 2015

NSU cancer researcher selected for prestigious J. William Fulbright award

Nova Southeastern University cancer researcher Appu Rathinavelu, Ph.D., was selected for a prestigious J. William Fulbright award to conduct cancer research and training in India. Dr. Rathinavelu is associate dean for institutional planning and development at NSU's College of Pharmacy and executive director of NSU's Rumbaugh-Goodwin Institute for Cancer Research.

9 Jul 2015

Ludwig, CRI launch clinical trials to evaluate immunotherapies for treatment of GBM and solid tumors

Ludwig Cancer Research and the Cancer Research Institute have launched clinical trials evaluating an immunotherapy for the treatment of the brain cancer glioblastoma multiforme (GBM), and a combination of immunotherapies for a variety of solid tumors.

8 Jul 2015

Novartis announces FDA approval of Entresto to reduce risk of cardiovascular death, heart failure hospitalization

Novartis announced today that the US Food and Drug Administration has approved Entresto™ tablets, previously known as LCZ696, to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure and reduced ejection fraction.

8 Jul 2015

Galmed signs License Agreement for development of blood-based companion diagnostic tool

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases, announced today that it has entered into a Research, Option and License Agreement ("License Agreement") and a Share Purchase Agreement with One Way Liver Genomics S.L., for the development of a non-invasive, blood-based companion diagnostic tool.

8 Jul 2015

Resverlogix and Hepalink close license agreement, sign definitive stock purchase agreement

Resverlogix Corp. announced today that it has closed a license agreement and formally entered into a definitive stock purchase agreement with Shenzhen Hepalink Pharmaceutical Co., Ltd..

8 Jul 2015

Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains.

8 Jul 2015

Immune Pharmaceuticals amends licensing agreement with Endo Pharmaceuticals

Immune Pharmaceuticals, Inc. announced today that it has amended its 2003 Licensing Agreement with Endo Pharmaceuticals Inc., a subsidiary of Endo International plc. As a result, Immune will transfer to Endo its previously licensed patents related to the use of topical lidocaine in acute and chronic back pain and Endo will grant Immune a royalty-free, non-exclusive, fully transferable license to those patents.

8 Jul 2015

Southern Research receives $22 million to support HIV cure initiative

Southern Research has been awarded a seven-year contract of up to $22 million to support research that could contribute to the cure of HIV disease. Under this contract, Southern Research will develop and standardize assays that quantitate latent reservoirs of HIV.

7 Jul 2015

Aytu BioScience now trading under new symbol following its corporate name change

Aytu BioScience, Inc., a specialty healthcare company focused on developing treatments for urological and related conditions, announced today that the company is now trading under the new symbol "AYTU," following its corporate name change, which became effective June 8, 2015.

7 Jul 2015

Abide Therapeutics begins Phase 1a study of ABX-1431 investigational endocannabinoid system modulator

Abide Therapeutics, a developer of innovative pharmaceuticals, announced today initiation of enrollment and dosing of the first subject in a Phase 1a clinical study of ABX-1431, a first-in-class, investigational endocannabinoid system modulator.

7 Jul 2015

Hi-Tech enters into definitive agreement to acquire Innovative's brand of Diet Aids

Hi-Tech Pharmaceuticals, a leading global provider of Sports Nutrition, Weight loss products, and Contract Manufacturing services, and Innovative laboratories, one of the fastest-growing Weight Loss brands in the United States, today announced that they have entered into a definitive agreement in which Hi-Tech has agreed to acquire Innovative's brand of Diet Aids.

7 Jul 2015

Findings reveal new pathway to develop effective treatments and therapies for asthma, allergy

Investigators have discovered the precise molecular steps that enable immune cells implicated in certain forms of asthma and allergy to develop and survive in the body. The findings from Weill Cornell Medical College reveal a new pathway that scientists could use to develop more effective treatments and therapies for the chronic lung disorder.

7 Jul 2015

Pharmaceuticals News and Research

Study offers new way to suppress growth factors related to cancer cell proliferation

Envarsus XR receives FDA approval for treatment of kidney transplant recipients

Four young scientists named recipients of Damon Runyon-Sohn Pediatric Cancer Research Fellowship Award

Tillotts Pharma to purchase global rights for AstraZeneca’s Entocort excluding the U.S.

Elsevier, NCI implement two-way linking between research articles on ScienceDirect and datasets in caNanoLab

Sorrento, NantBioScience form joint venture to develop targeted therapies against cancer

Phase 3 ODYSSEY JAPAN trial of Praluent injection meets primary endpoint

Partnerships between healthcare insurers and pharmaceutical companies promote real-world value

NSU cancer researcher selected for prestigious J. William Fulbright award

Ludwig, CRI launch clinical trials to evaluate immunotherapies for treatment of GBM and solid tumors

Novartis announces FDA approval of Entresto to reduce risk of cardiovascular death, heart failure hospitalization

Galmed signs License Agreement for development of blood-based companion diagnostic tool

Resverlogix and Hepalink close license agreement, sign definitive stock purchase agreement

Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

Immune Pharmaceuticals amends licensing agreement with Endo Pharmaceuticals

Southern Research receives $22 million to support HIV cure initiative

Aytu BioScience now trading under new symbol following its corporate name change

Abide Therapeutics begins Phase 1a study of ABX-1431 investigational endocannabinoid system modulator

Hi-Tech enters into definitive agreement to acquire Innovative's brand of Diet Aids

Findings reveal new pathway to develop effective treatments and therapies for asthma, allergy

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring